MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy

BACKGROUND: Tamoxifen (TAM) and fulvestrant (FUL) are the major drugs for patients with estrogen receptor-positive (ER(+)) breast cancers. However, the development of endocrine resistance is the impediment for successful treatment. We aimed to explore the mechanisms of endocrine resistance and thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xinfeng, Luo, Aiping, Liu, Yicong, Wang, Shuqing, Li, Ye, Shi, Wenna, Liu, Zhihua, Qu, Xianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678692/
https://www.ncbi.nlm.nih.gov/pubmed/26666173
http://dx.doi.org/10.1186/s12943-015-0480-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678692/
https://www.ncbi.nlm.nih.gov/pubmed/26666173
http://dx.doi.org/10.1186/s12943-015-0480-4

Ejemplares similares